New drug combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that cannot be removed with surgery and has spread to other parts of the body.
- Your cancer has a normal (wild-type) RAS and BRAF gene, meaning no mutations in these genes.
- You have already tried at least three chemotherapy drugs (oxaliplatin, fluorouracil, and irinotecan) and also tried cetuximab or bevacizumab, but your cancer continued to grow.
- You are between 18 and 75 years old, in fairly good health (able to do daily activities), and expected to live more than 3 months.
- You must not have had previous treatment with drugs that target both EGFR and c-Met pathways at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called TQB2102 for colorectal cancer that has HER2-positive tumors and has stopped responding to standard treatments. The drug targets HER2 to try to slow or stop cancer growth.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a new drug combination for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug designed to slow or stop the growth of advanced colorectal cancer that has spread and can't be removed with surgery. It may be an option if standard treatments have stopped working or aren't suitable for you.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
Hear when a new RAS/BRAF Wild Type Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.